Eikon Therapeutics, Inc.

Eikon Therapeutics is a clinical biopharmaceutical company focused on developing medicines to address serious unmet medical needs. Its lead product candidate is EIK1001, a systemically administered TLR 7/8 dual-agonist designed to activate both innate and adaptive immune anti-tumor responses. The company also has a portfolio of selective PARP1 inhibitors, including EIK1003 and EIK1004, targeting ovarian, breast, prostate, and pancreatic cancers. EIK1004 is brain-penetrant, making it potentially useful for brain metastases and primary brain malignancies. Additionally, EIK1005 is a potent WRN helicase inhibitor for MSI-high tumors, and EIK1006 is a next-generation androgen receptor antagonist active against multiple clinically emergent androgen receptor variants.

Eikon Therapeutics is listed on the Nasdaq Global Select Market (NasdaqGS) under the ticker symbol EIKN. The company's shares are traded in US Dollars (USD). As a US-based company, its primary listing is on this major US exchange, providing liquidity and visibility to investors.

Eikon Therapeutics operates in the Healthcare sector, specifically within the Biotechnology industry. As a clinical biopharmaceutical company, it focuses on researching and developing novel therapies for cancer and other serious diseases. Biotechnology companies like Eikon use biological processes and molecular biology to create drugs, often targeting specific pathways or mechanisms involved in disease.

Eikon Therapeutics is headquartered in Millbrae, California, United States. The company was incorporated in 2019. Being based in the San Francisco Bay Area places it within a major hub for biotechnology and pharmaceutical innovation, providing access to talent, research institutions, and potential partners.

Eikon Therapeutics has a pipeline of several product candidates targeting various cancers. EIK1001 is a TLR 7/8 dual-agonist that activates immune responses against tumors. The PARP1 inhibitors EIK1003 and EIK1004 are designed for ovarian, breast, prostate, and pancreatic cancers, with EIK1004 being brain-penetrant for brain metastases and primary brain tumors. EIK1005 is a WRN helicase inhibitor for MSI-high tumors, and EIK1006 is an androgen receptor antagonist for prostate cancer. These candidates are in clinical development, aiming to address significant unmet medical needs.